text.skipToContent text.skipToNavigation

Maximum quantity allowed is 999

Please select the quantity

CAS RN: 3094-09-5 | Product Number: D3579

5'-Deoxy-5-fluorouridine


Purity: >98.0%(T)(HPLC)
Synonyms:
  • 5'-dFUrd
  • Doxifluridine
  • 1-(5-Deoxy-β-D-ribofuranosyl)-5-fluorouracil
Product Documents:
1G
€46.00
1   ≥60 
5G
€148.00
1   ≥100 

*Stock available in Belgium will be delivered in 1 to 3 days
*Stock available in Japan will be delivered in 1 to 2 weeks (excludes regulated items and dry ice shipments).


Product Number D3579
Purity / Analysis Method >98.0%(T)(HPLC)
Molecular Formula / Molecular Weight C__9H__1__1FN__2O__5 = 246.19 
Physical State (20 deg.C) Solid
Storage Temperature Room Temperature (Recommended in a cool and dark place, <15°C)
CAS RN 3094-09-5
Reaxys Registry Number 890191
PubChem Substance ID 87559877
Merck Index (14) 3437
MDL Number

MFCD00866530

Specifications
Appearance White to Almost white powder to crystal
Purity(HPLC) min. 98.0 area%
Purity(Neutralization titration) min. 98.0 %
Melting point 189.0 to 193.0 °C
Specific rotation [a]20/D +18.0 to +22.0 deg(C=1, H2O)
Properties (reference)
Melting Point 189 °C
Specific Rotation 20° (C=1,H2O)
GHS
Pictogram Pictogram Pictogram
Signal Word Warning
Hazard Statements H373 : May cause damage to organs through prolonged or repeated exposure.
H317 : May cause an allergic skin reaction.
Precautionary Statements P501 : Dispose of contents/ container to an approved waste disposal plant.
P260 : Do not breathe dust.
P280 : Wear protective gloves.
P314 : Get medical advice/ attention if you feel unwell.
P362 + P364 : Take off contaminated clothing and wash it before reuse.
P333 + P313 : If skin irritation or rash occurs: Get medical advice/ attention.
Related Laws:
EC Number 221-440-1
RTECS# YU7526000
Transport Information:
HS Number 2940000080
Application
5'-Deoxy-5-Fluorouridine (Doxifluridine): A Prodrug of Active Antitumor 5-FU

5'-Deoxy-5-fluorouridine (doxifluridine) is a prodrug of active antitumor 5-FU [F0151] and an intermediary metabolite of capecitabine [C2878] and 5'-deoxy-5-fluorocytidine [D4342]. The activation of capecitabine follows a pathway with three enzymatic steps and two intermediary metabolites, 5'-deoxy-5-fluorocytidine and doxifluridine, to form 5-FU. Capecitabine and its intermediary metabolites are not cytotoxic by themselves. The final step (doxifluridine to 5-FU) requires thymidine phosphorylase (dThdPase) that is significantly more active in tumor than normal tissue. This tumor-selective delivery of 5-FU ensured greater efficacy and a more favorable safety profile than with other fluoropyrimidines. (The product is for research purpose only.)

References


PubMed Literature


TCIMAIL
Product Documents (Note: Some products will not have analytical charts available.)
Safety Data Sheet (SDS)
Please select Language.

The requested SDS is not available.

Please Contact Us for more information.

Specifications
C of A & Other Certificates
Please enter Lot Number Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.

The product with the lot number searched for has been discontinued and no related documentation is available.

Sample C of A
This is a sample C of A and may not represent a recently manufactured lot of the product.

A sample C of A for this product is not available at this time.

Analytical Charts
Please enter Lot Number Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.

The requested analytical chart is not available. Sorry for the inconvenience.

The product with the lot number searched for has been discontinued and no related documentation is available.

Other Documents

Session Status
Your session will timeout in 10 minutes. You will be redirected to the HOME page after session timeout. Please click the button to continue session from the same page. minute. You will be redirected to the HOME page after session timeout. Please click the button to continue session from the same page.

Your session has timed out. You will be redirected to the HOME page.